Skip to content

Study · Randomized controlled trial · n = 46 · 2014

4 results

Cerebrolysin effects on neurological outcomes and cerebral blood flow in acute ischemic stroke.

Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B, Mokari T, Tahamtan U, Rezaei Y

Neuropsychiatric disease and treatment3 Dec 2014Cited by 38 (Europe PMC)

PMID25516711 (opens in a new tab)PMCIDPMC4263193 (opens in a new tab)DOI10.2147/ndt.s75304 (opens in a new tab)PepBankPUB-25516711
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, Cerebrolysin lowered NIHSS versus placebo on day 60.

    In plain wordsIn stroke patients, Cerebrolysin lowered the neurological deficit score versus placebo on day 60.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS at day 60
    Study

    n = 46

    Comparator
    Normal saline placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL daily · intravenous · 10 daysAs given in this study (human).

    Measurements

    NIHSS median
    10 NIHSS score
    Cerebrolysin versus placebo on day 60, as reported in the summary
    NIHSS interquartile range
    9 to 11 NIHSS score
    Cerebrolysin versus placebo on day 60, as reported in the summary
    P value for NIHSS: cerebrolysin versus placebo
    0.008 unitless
    Cerebrolysin versus placebo on day 60, as reported in the summary

    Source sentences

    Summary
    The National Institutes of Health Stroke Scale was significantly lower in the cerebrolysin group compared with the placebo group on day 60 (median 10, interquartile range 9-11, P=0.008) and day 90 (median 11, interquartile range 10-13.5, P=0.001).
    1 context sentence
    Summary · context
    In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, Cerebrolysin lowered NIHSS versus placebo on day 90.

    In plain wordsIn stroke patients, Cerebrolysin lowered the neurological deficit score versus placebo on day 90.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS at day 90
    Study

    n = 46

    Comparator
    Normal saline placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 mL daily · intravenous · 10 daysAs given in this study (human).

    Measurements

    NIHSS median
    11 NIHSS score
    Cerebrolysin versus placebo on day 90, as reported in the summary
    NIHSS interquartile range
    10 to 13.5 NIHSS score
    Cerebrolysin versus placebo on day 90, as reported in the summary
    P value for NIHSS: cerebrolysin versus placebo
    0.001 unitless
    Cerebrolysin versus placebo on day 90, as reported in the summary

    Source sentences

    Summary
    The National Institutes of Health Stroke Scale was significantly lower in the cerebrolysin group compared with the placebo group on day 60 (median 10, interquartile range 9-11, P=0.008) and day 90 (median 11, interquartile range 10-13.5, P=0.001).
    1 context sentence
    Summary · context
    In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In acute ischemic stroke patients, Cerebrolysin lowered right middle cerebral artery pulsatility index versus placebo on days 30, 60, and 90.

    In plain wordsIn stroke patients, Cerebrolysin lowered the artery pulsatility index versus placebo on days 30, 60, and 90.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseRight middle cerebral artery pulsatility index
    Study

    n = 46

    Comparator
    Normal saline placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    30 mL daily · intravenous · 10 daysAs given in this study (human).

    Measurements

    P value for right middle cerebral artery pulsatility index
    < 0.05 unitless
    Right middle cerebral artery PI: cerebrolysin versus placebo on days 30, 60, and 90

    Source sentences

    Summary
    The median of PI in the right middle cerebral artery was significantly lower in the cerebrolysin group compared with the placebo group on days 30, 60, and 90 (P<0.05).
    1 context sentence
    Summary · context
    In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily.
  4. 04HumanRandomized controlled trialSafety outcome

    In acute ischemic stroke patients, deaths before day 30 occurred in 4.3% with Cerebrolysin versus 8.7% with placebo.

    In plain wordsIn stroke patients, deaths before day 30 occurred in 4.3% with Cerebrolysin versus 8.7% with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseDeaths before day 30
    Study

    n = 46

    Comparator
    Normal saline placebo
    Outcome group
    Mortality · Whole body
    Studied dose
    30 mL daily · intravenous · 10 daysAs given in this study (human).

    Measurements

    Deaths
    4.3%
    Cerebrolysin
    Deaths
    8.7%
    placebo
    Deaths before day 30
    1 patient
    Cerebrolysin group, before day 30
    Deaths before day 30
    2 patients
    Placebo group, before day 30

    Source sentences

    Summary
    One patient in the cerebrolysin group and two patients in the placebo group died before day 30 (4.3% versus 8.7%).
    1 context sentence
    Summary · context
    In a randomized, double-blinded, placebo-controlled trial, 46 patients who had acute focal ischemic stroke were randomly assigned into two groups to receive intravenously either 30 mL of cerebrolysin diluted in normal saline daily for 10 days (n=23) or normal saline alone (n=23) adjunct to 100 mg of aspirin daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.